Friday, May 14, 2021 4:12:30 AM
Income/profit:
As per 1Q 2020 (loss in Q1 2020), net profit (+$36K) is relatively low compared to income ($437K). As per SB, charges paid and booked versus income to receive, could/should be the reason.
General expenses (30.8K) are small. Most of the expenses are in the "Cost of goods" section. Mainly Direct Labor (158.7K), Job materials (73.4K) adn Union Benefit (104.5K).
In other terms, they have been busy working this Q1
Note the there was no "profit sharing" this time. Still wondering with whom they shared some profits...? What introducer or client provider... ? what kind of agreement brought this profit sharing... ?
Assets:
new vehicles.. value is up +49.5K
A nice chunk of the receivable were effectively received.. Plenty of cash at the bank
The "investment CS 8306" value hasn't been updated. Certainly using the investment cost as value.
Still a mystery what this investment is ? CS for charging station ? Whatever it is, hopefully this will turn out as a good investment in 2021
Liabilities
Bank credit line repaid (-50k)
Payroll liabilities decreased (-50K)
New notes to A.A.C. and Chrysler Capital for a total of 83.5K (+83.5K)
All together, liabilities are down to 288.5K (vs 305.8K end Dec 2020).
Conclusion:
a) Balance sheet improved as per what has been done in 2020: less liabilities, more cash.
b) Value of the investment unclear
c) strong sales with charges indicating that a lot of work has been perfomed
d) probability that some of the costs booked this quarter will generate the income only in Q2
e) Ma little two cents advise to them... please spend some money under "marketing" or add a nice "investor relations charges" new line
last but not least:
no change regarding O/S... even after some told us the scary "dilution" was at play each time we had volume
- Some of the less friendly observers have determined that we will abandon our principles and reveal ourselves as shallow cynical exploiters. We must disappoint them... quite simply put, we walk our talk -
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM